your market intelligence analyst
Search Results
10 results
Your search is now limited to «Cancer Drugs» expert search.
Your search is now limited to only one Source. To return to results from all sources click here. 08/22/2019 08:39
Conditions : Multiple Myeloma; Relapsed Refractory Multiple Myeloma Interventions : Drug: Elotuzumab, pomalidomide, dexamethasone; Drug: Anti-LAG-3 Monoclonal Antibody BMS-986016, pomalidomide, dexamethasone; Drug: Anti-TIGIT Monoclonal Antibody BMS-986207, pomalidomide, dexamethasone Sponsors : Multiple Myeloma Research Consortium; Bristol-Myers Squibb Not yet recruiting. 08/12/2019 08:12
Conditions : Bilateral Breast Carcinoma; Breast Carcinoma; HER2/Neu Negative; Mastectomy Patient; Recurrent Breast Carcinoma; Triple-Negative Breast Carcinoma Interventions : Drug: ATR Kinase Inhibitor M6620; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy Sponsor : National Cancer Institute (NCI) Not yet recruiting. 07/31/2019 07:44
Sacituzumab govitecan is believed to work by binding the antibody portion of the drug to the tumor(s) while the anticancer drug portion works to prevent the cancer cells from growing/spreading. 07/29/2019 07:49
Conditions : Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Germline BRCA1 Gene Mutation; Germline BRCA2 Gene Mutation; High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Ovarian Clear Cell Tumor; Ovarian Seromucinous Carcinoma; Ovarian Undifferentiated Carcinoma; Platinum-Sensitive Fallopian Tube Carcinoma; Platinum-Sensitive Ovarian Carcinoma; Platinum-Sensitive Primary Peritoneal Carcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Clear Cell Carcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Primary Peritoneal Transitional Cell Carcinoma; Primary Peritoneal Undi. 06/13/2019 07:33
Conditions : BCL2 Gene Translocation; C-Myc Translocation; Diffuse Large B-Cell Lymphoma; Double-Expressor Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present Interventions : Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Etoposide; Drug: Prednisone; Biological: Rituximab; Drug: Venetoclax; Drug: Vincristine; Drug: Vincristine Sulfate Sponsor : National Cancer Institute (NCI) Not yet recruiting.

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications